Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

GLP-Compliant Pathology for Biodistribution Studies of Oligonucleotide Therapeutics in Berlin

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

GLP-Compliant Pathology for Biodistribution Studies of Oligonucleotide Therapeutics in Berlin

GxP-Compliant Pathology for Oligonucleotide Biodistribution Studies

CELL & GENE | RNA | BIOLOGICS

    What specific histology techniques are used to assess oligonucleotide distribution in GxP studies?

    We primarily utilize In Situ Hybridization (ISH) with probes specific to your oligonucleotide sequence for direct visualization within tissues. This is complemented by Immunohistochemistry (IHC) to evaluate downstream pharmacodynamic effects or cellular responses. All assays are supported by whole-slide imaging and quantitative digital pathology for objective analysis.

    How does Franklin Biolabs ensure GxP compliance for its pathology data?

    Our facility operates under a stringent quality management system. This includes dedicated Quality Assurance oversight for all study phases, fully validated software and instrumentation, version-controlled Standard Operating Procedures (SOPs), and review by board-certified pathologists trained in GxP documentation practices.

    What is the typical timeline for a full tissue set analysis in a biodistribution study?

    While each study is unique, our streamlined workflows are designed to support an 18-24 month Investigational New Drug (IND) timeline. We prioritize efficient data delivery to align with aggressive program milestones, and a detailed schedule is established as part of the initial study protocol.

    Can you accommodate custom staining protocols for novel oligonucleotide conjugates?

    Yes. We have a defined, phase-appropriate process for the development, optimization, and validation of novel staining protocols. Our scientific team collaborates directly with yours to ensure the assay meets the specific requirements for your therapeutic construct and its intended mechanism of action.

To support IND submissions for oligonucleotide therapeutics, a precise characterization of the molecule’s biodistribution is required by regulatory bodies. This involves generating robust, GxP-compliant pathology data to identify target tissue engagement and map potential non-target tissue accumulation. Our specialized histology and quantitative digital pathology services deliver a clear, defensible data package that defines the tissue and cellular localization of your asset, de-risking downstream clinical development.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Defining the Biodistribution Profile for IND Submission

The safety and efficacy profile of an oligonucleotide therapeutic is directly linked to its distribution profile. Understanding where the asset accumulates, both in target and non-target tissues, is fundamental to building a successful IND application. Inaccurate or incomplete biodistribution data can lead to significant delays and requests for additional studies from regulatory authorities.

The systemic distribution of advanced therapeutics can present unexpected challenges. For instance, studies examining other advanced modalities have shown that a high percentage of a dose administered to a localized compartment can still distribute systemically (PMID: 37624734). This principle underscores the necessity of conducting comprehensive whole-body biodistribution assessments for oligonucleotides to fully understand potential liabilities related to dosing, immunogenicity, and toxicity. Our >100,000 sq ft facility is equipped to manage these complex IND-enabling programs.

Watch the full-length video ‘DIVERSIFYING THE VALUE CHAIN’

Quantitative Pathology for IND-Enabling Studies

Our approach integrates classical histology with modern quantitative methods to provide a complete picture of your asset’s in vivo behavior. Since the 2024 launch of the Franklin Biolabs brand, our scientific leadership has maintained a 100% IND-enabling success rate on programs initiated since 2019.

  • In Situ Hybridization (ISH): We employ validated ISH protocols to directly detect your oligonucleotide sequence within tissue sections, providing unambiguous evidence of cellular and subcellular localization.

  • Whole-Slide Imaging (WSI): Every slide is digitized at high resolution, creating a permanent digital record and enabling objective, algorithm-driven analysis.

  • Quantitative Digital Pathology: We use validated image analysis algorithms to quantify the intensity and distribution of staining, moving beyond qualitative assessment to generate robust numerical data suitable for regulatory review.

  • Pathologist Review: All findings are interpreted by board-certified pathologists with expertise in novel therapeutic modalities, providing context to the quantitative data.

This integrated workflow provides the rapid pathology insights accelerating preclinical readouts that are necessary to meet aggressive development timelines.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Comparison of Biodistribution Assessment Methodologies

Methodology Target Analyte Spatial Resolution GxP Applicability
qPCR / LC-MS Oligonucleotide Low (Homogenate) High
In Situ Hybridization Oligonucleotide High (Cellular) High
Immunohistochemistry PD Biomarker High (Cellular) High
Autoradiography (WBA) Radiolabeled Drug Medium (Tissue) High

Commitment to Animal Welfare

All in vivo studies are conducted in strict accordance with animal welfare regulations. Our programs are designed around the 3Rs principles (Reduction, Refinement, and Replacement) to minimize animal use while maximizing data quality. Franklin Biolabs and its strategic partners maintain full AAALAC accreditation and USDA registration.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities